ots-412
Biologicalexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 4, 2022 (NCT07302945)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Oncolytic virusSupplementation
Oncolytic virus supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07170592 | Phase 1 | Dec 31, 2025 | Bionoxx Inc. |
| NCT07190833 | Phase 1 | Nov 30, 2025 | Bionoxx Inc. |
| NCT07302945 | Early Phase 1 (Phase 1) | Jan 4, 2022 | Bionoxx Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bionoxx Inc. | For profit | 3 | 3 | 1 | 2022 |
1 organizations
Page 1 / 1